How much profit has Biocartis Group made this year?
Biocartis Group has made -91.18 M EUR this year.
Biocartis Group Net Income 2024
Biocartis Group Net Income
-91.18 M EUR
Ticker
BCART.BR
ISIN
BE0974281132
WKN
A14R82
In 2024, Biocartis Group's profit amounted to -91.18 M EUR, a -25.79% increase from the -122.86 M EUR profit recorded in the previous year.
The Biocartis Group Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2025e | - |
| 2024e | - |
| 2023e | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
Biocartis Group Revenue, EBIT, Net Income BE0974281132 · A14R82
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Biocartis Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biocartis Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biocartis Group’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Biocartis Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Biocartis Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Biocartis Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biocartis Group’s growth potential.
Biocartis Group Revenue, EBIT and net profit per share
| Date | Biocartis Group Revenue | Biocartis Group EBIT | Biocartis Group Net Income |
|---|---|---|---|
| 2025e | 103 M undefined | 4.12 M undefined | -47.4 M undefined |
| 2024e | 78.28 M undefined | -18.54 M undefined | -91.18 M undefined |
| 2023e | 59.74 M undefined | -36.05 M undefined | -122.86 M undefined |
| 2022 | 57.48 M undefined | -47.05 M undefined | -65.38 M undefined |
| 2021 | 48.27 M undefined | -62.65 M undefined | -71.47 M undefined |
| 2020 | 43.13 M undefined | -46.86 M undefined | -62.93 M undefined |
| 2019 | 37.44 M undefined | -55.6 M undefined | -64.07 M undefined |
| 2018 | 27.81 M undefined | -46.86 M undefined | -48.15 M undefined |
| 2017 | 20.96 M undefined | -43.59 M undefined | -41.96 M undefined |
| 2016 | 12.1 M undefined | -50.17 M undefined | -49.78 M undefined |
| 2015 | 13.33 M undefined | -39.66 M undefined | -39.8 M undefined |
| 2014 | 8.48 M undefined | -29.17 M undefined | -9.12 M undefined |
| 2013 | 8.33 M undefined | -26.37 M undefined | -35.62 M undefined |
| 2012 | 3.55 M undefined | -35.8 M undefined | -44.43 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2012 | 3.55 M EUR | -35.8 M EUR | -44.43 M EUR |
| 2013 | 8.33 M EUR | -26.37 M EUR | -35.62 M EUR |
| 2014 | 8.48 M EUR | -29.17 M EUR | -9.12 M EUR |
| 2015 | 13.33 M EUR | -39.66 M EUR | -39.8 M EUR |
| 2016 | 12.1 M EUR | -50.17 M EUR | -49.78 M EUR |
| 2017 | 20.96 M EUR | -43.59 M EUR | -41.96 M EUR |
| 2018 | 27.81 M EUR | -46.86 M EUR | -48.15 M EUR |
| 2019 | 37.44 M EUR | -55.6 M EUR | -64.07 M EUR |
| 2020 | 43.13 M EUR | -46.86 M EUR | -62.93 M EUR |
| 2021 | 48.27 M EUR | -62.65 M EUR | -71.47 M EUR |
| 2022 | 57.48 M EUR | -47.05 M EUR | -65.38 M EUR |
| 2023e | 59.74 M EUR | -36.05 M EUR | -122.86 M EUR |
| 2024e | 78.28 M EUR | -18.54 M EUR | -91.18 M EUR |
| 2025e | 103 M EUR | 4.12 M EUR | -47.4 M EUR |
Biocartis Group stock margins BE0974281132 · A14R82
The Biocartis Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biocartis Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biocartis Group.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Biocartis Group's sales revenue. A higher gross margin percentage indicates that the Biocartis Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Biocartis Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Biocartis Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biocartis Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biocartis Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biocartis Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Biocartis Group Margin History
| Biocartis Group Gross margin | Biocartis Group Profit margin | Biocartis Group EBIT margin | Biocartis Group Profit margin |
|---|---|---|---|
| 2025e | 48.16 % | 4 % | -46.02 % |
| 2024e | 48.16 % | -23.68 % | -116.47 % |
| 2023e | 48.16 % | -60.34 % | -205.65 % |
| 2022 | 48.16 % | -81.85 % | -113.74 % |
| 2021 | 29.72 % | -129.78 % | -148.07 % |
| 2020 | 39.06 % | -108.66 % | -145.92 % |
| 2019 | 43.04 % | -148.49 % | -171.1 % |
| 2018 | 44.81 % | -168.49 % | -173.14 % |
| 2017 | 58.62 % | -207.99 % | -200.22 % |
| 2016 | 56.03 % | -414.7 % | -411.45 % |
| 2015 | 80.19 % | -297.4 % | -298.46 % |
| 2014 | 50.65 % | -344.1 % | -107.55 % |
| 2013 | 77.07 % | -316.57 % | -427.61 % |
| 2012 | 68.17 % | -1,008.45 % | -1,251.55 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2012 | 68.17 % | -1,008.45 % | -1,251.55 % |
| 2013 | 77.07 % | -316.57 % | -427.61 % |
| 2014 | 50.65 % | -344.1 % | -107.55 % |
| 2015 | 80.19 % | -297.4 % | -298.46 % |
| 2016 | 56.03 % | -414.7 % | -411.45 % |
| 2017 | 58.62 % | -207.99 % | -200.22 % |
| 2018 | 44.81 % | -168.49 % | -173.14 % |
| 2019 | 43.04 % | -148.49 % | -171.1 % |
| 2020 | 39.06 % | -108.66 % | -145.92 % |
| 2021 | 29.72 % | -129.78 % | -148.07 % |
| 2022 | 48.16 % | -81.85 % | -113.74 % |
| 2023e | 48.16 % | -60.34 % | -205.65 % |
| 2024e | 48.16 % | -23.68 % | -116.47 % |
| 2025e | 48.16 % | 4 % | -46.02 % |
Biocartis Group Aktienanalyse
What does Biocartis Group do?
Biocartis Group NV is a Belgian biotechnology company specializing in the development and marketing of innovative diagnostic test systems. The company was founded in 2007 and is headquartered in Mechelen, Belgium. Biocartis focuses on various disease areas such as gynecology, oncology, infectious diseases, and immunology. Biocartis' business model is based on a unique diagnostic test system called Idylla, which allows for rapid testing within hours instead of the usual weeks. The Idylla platform also offers high accuracy in identifying biomarkers and easy handling for medical personnel. The company has certified distribution partners worldwide to support the marketing and sales of Biocartis products. Biocartis collaborates closely with pharmaceutical companies, medical laboratories, and clinics globally to deliver the best results for its customers. The company also has partnerships with other biotech companies like Merck and Genomic Health to support the development of its diagnostic tests. Biocartis offers a wide range of diagnostic tests for various cancer types, gynecology, and infectious diseases. Their tests help physicians identify the type and extent of tumors and monitor patients' health status. Through the development and marketing of innovative diagnostic test systems, Biocartis aims to improve disease diagnosis and monitoring, ultimately enhancing treatment for patients worldwide. Overall, Biocartis is a leading company in the biotechnology industry specializing in the development and marketing of innovative diagnostic test systems for various disease areas. With its certified distribution partners and partnerships with other biotech companies, Biocartis has a strong presence in the global market and is well positioned to continue being a key player in the biomedical diagnostics industry. Biocartis Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Biocartis Group's Profit Margins
The profit margins of Biocartis Group represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Biocartis Group's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Biocartis Group's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Biocartis Group's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Biocartis Group’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Biocartis Group stock
How has the profit developed compared to last year?
The profit has increased by -25.79% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Biocartis Group publish its earnings?
Biocartis Group publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Biocartis Group?
The profits of Biocartis Group are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Biocartis Group?
You can learn more about the earnings of Biocartis Group by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Biocartis Group pay?
Over the past 12 months, Biocartis Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biocartis Group is expected to pay a dividend of 0 EUR.
What is the dividend yield of Biocartis Group?
The current dividend yield of Biocartis Group is .
When does Biocartis Group pay dividends?
Biocartis Group pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biocartis Group?
Biocartis Group paid dividends every year for the past 0 years.
What is the dividend of Biocartis Group?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biocartis Group located?
Biocartis Group is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biocartis Group kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biocartis Group from 12/4/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.
When did Biocartis Group pay the last dividend?
The last dividend was paid out on 12/4/2024.
What was the dividend of Biocartis Group in the year 2023?
In the year 2023, Biocartis Group distributed 0 EUR as dividends.
In which currency does Biocartis Group pay out the dividend?
The dividends of Biocartis Group are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Biocartis Group
Our stock analysis for Biocartis Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocartis Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Biocartis Group Revenue
- Biocartis Group Net Income
- Biocartis Group P/E
- Biocartis Group P/S
- Biocartis Group EBIT
- Biocartis Group Dividend
- Biocartis Group Stocks
- Biocartis Group Market capitalization
- Biocartis Group Debt
- Biocartis Group Liabilities
- Biocartis Group Equity
- Biocartis Group AAQS
- Biocartis Group Employees
- Biocartis Group ROE
- Biocartis Group ROA
- Biocartis Group ROCE
